SK bioscience Secures Major Funding to Propel RSV Antibody Development Globally SK bioscience has secured funding from the RIGHT Foundation to advance the development of an RSV preventive monoclonal antibody. This pivotal support will enhance clinical trials for transforming global health.

SK bioscience Secures Major Funding to Propel RSV Antibody Development Globally #South_Korea #Incheon #SK_bioscience #RSV_antibody #RIGHT_Foundation

Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe SK bioscience, IDT Biologika, and Vaxxas join forces to develop next-generation influenza vaccines, aiming to enhance public health resilience and accessibility.

Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe #South_Korea #Incheon #SK_bioscience #IDT_Biologika #Vaxxas

SK bioscience Advances RSV Prevention with Novel Monoclonal Antibody Through Gates MRI License SK bioscience is set to develop a new monoclonal antibody for RSV prevention, showcasing a commitment to equitable global health through a recent partnership with Gates MRI.

SK bioscience Advances RSV Prevention with Novel Monoclonal Antibody Through Gates MRI License #South_Korea #RSV #Incheon #SK_bioscience #Gates_Medical_Research

SK bioscience Launches Phase 1/2 Trial for Universal Sarbecovirus Vaccine in Australia SK bioscience has commenced a global Phase 1/2 trial in Australia for GBP511, a universal vaccine targeting the sarbecovirus family, aiming for pandemic preparedness.

SK bioscience Launches Phase 1/2 Trial for Universal Sarbecovirus Vaccine in Australia #Australia #Incheon #SK_bioscience #GBP511 #SKYCovione

New Collaboration to Accelerate Zaire Ebola Vaccine Development with CEPI Support SK bioscience collaborates with MSD and Hilleman Labs, backed by CEPI funding, to enhance the Zaire ebolavirus vaccine accessibility and stability.

New Collaboration to Accelerate Zaire Ebola Vaccine Development with CEPI Support #South_Korea #Incheon #SK_bioscience #MSD #Zaire_Ebolavirus

IDT Biologika Accelerates Global CDMO Growth in Vaccines and Biopharmaceuticals IDT Biologika is enhancing its CDMO capabilities globally, focusing on vaccine production and biopharmaceuticals. Key global events highlighted its strengths in manufacturing.

IDT Biologika Accelerates Global CDMO Growth in Vaccines and Biopharmaceuticals #Germany #Frankfurt #CDMO #SK_bioscience #IDT_Biologika

SK bioscience Advances Towards First-in-Human Trial for Universal Coronavirus Vaccine in Australia SK bioscience has filed for a Phase 1/2 trial of its universal coronavirus vaccine in Australia, aiming to combat COVID-19 and related variants with results expected by 2028.

SK bioscience Advances Towards First-in-Human Trial for Universal Coronavirus Vaccine in Australia #Australia #Seongnam #COVID-19_vaccine #SK_bioscience #Universal_Vaccine

SK bioscience Takes Major Step Forward with IND Submission for 2-Dose Varicella Vaccine Phase 3 Trial SK bioscience has submitted an IND to initiate a Phase 3 trial for its 2-dose varicella vaccine, aligning with global vaccination standards and addressing rising market demand.

SK bioscience Takes Major Step Forward with IND Submission for 2-Dose Varicella Vaccine Phase 3 Trial #South_Korea #Seongnam #SK_bioscience #Varicella_Vaccine #SKYVaricella

SK bioscience and Gates Foundation Strengthen Global Health Initiatives Together SK bioscience recently met with the Gates Foundation to discuss advancements in global health and the development of next-generation preventive medicines. Discover more about their collaborative efforts.

SK bioscience and Gates Foundation Strengthen Global Health Initiatives Together #South_Korea #Seoul #Gates_Foundation #Global_Health #SK_bioscience

SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission SK bioscience has submitted an IND application for a Phase 1/2 clinical trial of a new adjuvanted influenza vaccine, aiming to enhance protective efficacy for vulnerable populations.

SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission #South_Korea #Seongnam #Influenza_vaccine #SK_bioscience #adjuvant_technology

SK Bioscience Achieves Legal Victory Against Pfizer in Pneumococcal Vaccine Patent Dispute SK Bioscience has won a crucial patent lawsuit against Pfizer regarding its pneumococcal vaccine, paving the way for future vaccine development and exportation.

SK Bioscience Achieves Legal Victory Against Pfizer in Pneumococcal Vaccine Patent Dispute #South_Korea #Seongnam #SK_bioscience #Pfizer #PCV13

IDT Biologika Amplifies Global Role via Strategic CDMO Alliances IDT Biologika is enhancing its global footprint through strategic partnerships and participation in major international bio events.

IDT Biologika Amplifies Global Role via Strategic CDMO Alliances #South_Korea #Seongnam #CDMO #SK_bioscience #IDT_Biologika

SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns SK bioscience collaborates with Korea Disease Control and Prevention Agency to create a rapid-response avian influenza vaccine to enhance global health security.

SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns #South_Korea #Seongnam #Avian_Influenza #SK_bioscience #Vaccine_Development

SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets SK bioscience has commenced the export of its SKYCellflu influenza vaccine to Southern Hemisphere markets, enhancing global vaccine access and production stability.

SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets #South_Korea #Seongnam #Influenza_vaccine #SK_bioscience #SKYCellflu

SK bioscience Launches Global Clinical Trials for mRNA Vaccine Against Japanese Encephalitis SK bioscience has initiated Phase 1/2 clinical trials of its mRNA vaccine for Japanese encephalitis, aiming for rapid pandemic response and global accessibility.

SK bioscience Launches Global Clinical Trials for mRNA Vaccine Against Japanese Encephalitis #South_Korea #Seongnam #SK_bioscience #mRNA_Vaccine #Japanese_Encephalitis

SK bioscience Launches mRNA Vaccine Trials for Japanese Encephalitis, Aiming for Global Impact SK bioscience has received approval for clinical trials of its mRNA vaccine candidate against Japanese encephalitis, aiming for swift global response.

SK bioscience Launches mRNA Vaccine Trials for Japanese Encephalitis, Aiming for Global Impact #South_Korea #Seongnam #SK_bioscience #mRNA_Vaccine #Japanese_Encephalitis